Ultra-low dose - new approaches in menopausal hormone therapy.

Stute, Petra; Becker, H-G; Bitzer, J; Chatsiproios, D; Luzuy, F; von Wolff, Michael; Wunder, D; Birkhäuser, M (2015). Ultra-low dose - new approaches in menopausal hormone therapy. Climacteric, 18(2), pp. 182-186. Informa Healthcare 10.3109/13697137.2014.975198

Full text not available from this repository.

Despite increasing life expectancy, the age of onset of natural menopause has not significantly changed in recent decades. Thus, women spend about one-third of their lives in an estrogen-deficient state if untreated. There is a need for appropriate treatment of acute symptoms and prevention of the sequelae of chronic estrogen deficiency. International guidelines call for the use of the lowest effective hormone dosage for vasomotor symptom relief, the major indication for menopausal hormone therapy (MHT). In 2011, an oral continuous combined ultra-low-dose MHT was approved in Switzerland. This publication was elaborated by eight national menopause specialists and intends to review the advantages and disadvantages of ultra-low-dose MHT after the first years of its general use in Switzerland. It concludes that, for many women, ultra-low-dose MHT may be sufficient to decrease vasomotor symptoms, but not necessarily to guarantee fracture prevention.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology
UniBE Contributor:	Stute, Petra, von Wolff, Michael
Subjects:	600 Technology > 610 Medicine & health
ISSN:	1369-7137
Publisher:	Informa Healthcare
Language:	English
Submitter:	Nathalie Ursula Becher
Date Deposited:	21 May 2015 14:39
Last Modified:	05 Dec 2022 14:47
Publisher DOI:	10.3109/13697137.2014.975198
PubMed ID:	25335192
Uncontrolled Keywords:	ESTROGEN; HORMONE THERAPY; MENOPAUSE; ULTRA-LOW DOSE
URI:	https://boris.unibe.ch/id/eprint/68925